Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
A Phase I, dose escalation study to evaluation the safety and
pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up
to 4 cycles of Epirubicin and Cyclophosphamide. 18 patients (6 patients each cohort) were
assigned to three escalated dose cohorts of 80, 240 and 320 µg/kg.